• Skip to primary navigation
  • Skip to main content
  • Skip to footer
PanTher Therapeutics

PanTher Therapeutics

  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact
homeNewsPanTher’s approach of “Attacking Cancer the Source” featured in the Nature Biopharma Dealmakers publication focused on the oncology landscape

PanTher’s approach of “Attacking Cancer the Source” featured in the Nature Biopharma Dealmakers publication focused on the oncology landscape

March 1, 2022 News

PanTher Therapeutics is targeting solid tumors through direct, localized, and sustained delivery of therapeutic agents. The company’s lead program is in a phase 1 trial, and the company is seeking partners to further develop its platform. Leveraging decades of material science, pharmacology, and cancer biology, PanTher’s innovative approach is truly differentiated from current technologies. In a highly competitive innovative drug discovery market, PanTher’s technology focuses on optimizing the route of administration to unlock a drug’s full potential.

Footer

Twitter LinkedIn

PanTher Therapeutics, Inc

191 Dexter Ave
Watertown, MA, 02472

PanTher Therapeutics © 2022 All Rights Reserved

Terms of Use Privacy Policy Cookie Policy Accessibility Statement

logo
  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact